Folinic acid (leucovorin or local equivalent)

Phase 3

Astellas Pharma (ALPMY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q1 '27

ALPMYPhase 3$24.1B

Folinic acid (leucovorin or local equivalent) Phase 3 Est. Readout

Folinic acid (leucovorin or local equivalent)• Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer500

Q1 2027~QConfirmed

CT.gov

00%

Competitive Landscape

0 competitors in Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

View Full Landscape

Drug Information

Target Indication

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Clinical Trial

NCT06901531

Last updated: 9/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

daclizumabPhase 3

Kidney Transplantation

SetidegrasibPhase 3

Pancreatic Cancer

YM177Phase 3

Post Operative Pain

micafungin (Mycamine)Phase 3

Fungemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts